National Institute of Allergy and Infectious Diseases
Link to NIAID Home Page Link to NIAID Home Page Link to NIH Home Page
NIAID Home Health & Science Research Funding Research News & Events Labs at NIAID About NIAID

Flu
 Understanding Flu
 Research
  Recent Findings
  Basic Research
  Diagnostic Progress
  Advances in Treatment
  Pandemic
  Vaccine Research
  Reports and Plans
  Clinical Studies
  NIAID Labs
  Service and Resources for Researchers


Flu (Influenza)

Advances in Treatment

Currently, there are four drugs available to treat the flu: oseltamivir (Tamiflu), zanamivir (Relenza), rimantadine (Flumadine), and amantadine (Symmetrel).

Rimantadine and amantadine (the adamantane drugs) are only effective against influenza A. Due to the development of drug resistance among influenza A viruses, the Centers for Disease Control and Prevention (CDC) has advised against the use of these two drugs. Oseltamivir and zanamivir (the neuraminidase inhibitors) are effective against influenza A and B, but, like the adamantanes, must be taken within 48 hours of infection to be effective.

NIAID supports research on influenza therapeutics to develop new drugs, determine effective drug combinations, and examine the mechanisms behind emerging drug resistance. This includes the support of innovative technologies used to design drugs that target specific viral proteins and cellular processes.

Research Features


Volunteer for NIAID-funded clinical studies related to flu on ClinicalTrials.gov.

Related Links

View a list of links for more information about influenza.

See Also

Influenza news releases

E-mail Icon E-mail this page
Print Icon Print this page


Volunteer for NIAID-funded clinical studies related to flu on ClinicalTrials.gov.

Related Links

View a list of links for more information about influenza.

See Also

Influenza news releases